Following the US FDA’s creation of a biosimilar educational campaign for physicians, the UK National Health Service (NHS) has recently launched a website to educate UK healthcare professionals and patients on biosimilars. Although biosimilar drugs [...]
Over the past year, there has been a lot of talk around how to reduce prescription drug prices in the US. However, there has been little consensus on the issue, which has made passing actual [...]
Although the FDA does not set drug prices, FDA commissioner, Scott Gottlieb, recognizes the important role the agency can play in lowering overall prescription drug prices by approving more generic drugs. Since taking office earlier [...]
Recent conversation regarding expanded access has focused heavily on the necessity of the FDA approval process. Right to Try legislation, which would remove the FDA from the expanded access process in the US, has been [...]
House Republicans recently released a tax reform bill which would eliminate the tax credits currently awarded to drug companies for developing drugs for rare diseases. These tax credits are part of a package of incentives [...]
Over the past decade, patient centricity has become an important buzzword in the healthcare sector. Defined as the process of designing and implementing a service or solution around the patient, patient centricity is now a [...]